The Carolyn Trial (ENG9) : A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying an immunomodulator (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18-75Age 18-75

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Head and neck,Lung,Skin,Stomach and upper gastrointestinal tract,Urinary systemBladder,Colon,Colorectum,Head and neck,Kidney,Lung,Melanoma (Skin),Non-Small Cell Lung Cancer,Pancreas,Rectum,Renal cell carcinoma,Urinary tract

Trial Overview Read MoreRead more

This phase I/II trial is evaluating the safety and effectiveness of a combination treatment for patients with advanced pancreatic cancer or other EGFR expressing cancers.
 

This trial is treating patients with pancreatic cancer or other EGFR expressing cancers.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying an immunomodulator (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate

Commercial Sponsor

EnGeneIC Pty Ltd

Summary

All patients enrolled in this clinical trial will receive a combination treatment, which contains the EnGeneIC Dream Vector (EDV(TM)), the study drug (chemotherapy) and the bispecific antibody. Treatment will be given in 8-week cycles and is combined in a syringe and administered intravenously, over a period of 20 minutes using a special pump. One dose of the treatment is given each week for the first 7 weeks, followed by a treatment free week (week 8) where a CT or MRI scan is performed to evaluate the tumours response.

Recruiting Hospitals Read MoreRead more

Peninsula & South Eastern Haematology and Oncology Group
Frankston
Mr Albert Goikman
ag@paso.com.au
03 9771 8918

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next